Aims. To evaluate the efficacy of
rosiglitazone (TZD) and
electroacupuncture (EA) combined
therapy as a treatment for
type 2 diabetes mellitus (T2DM) patients by randomized single-blind placebo controlled clinical trial. Methods. A total of 31 newly diagnostic T2DM patients, who fulfilled the study's eligibility criteria, were recruited. The individuals were randomly assigned into two groups, the control group (TZD, N = 15) and the experimental group (TZD + EA, N = 16). Changes in their plasma
free fatty acid (FFA),
glucose, and
insulin levels, together with their homeostasis model assessment (HOMA) indices, were statistically compared before and
after treatment.
Hypoglycemic activity (%) was also compared between these two groups. Results. There was no significant difference in
hypoglycemic activity between the TZD and TZD + EA group. The effectiveness of the combined
therapy seems to derive from an improvement in
insulin resistance and a significant lowering of the secreted
insulin rather than the effect of TZD alone on T2DM. The combined treatment had no significant adverse effects. A lower plasma FFA concentration is likely to be the mechanism that causes this effect. Conclusion. This combined
therapy seems to suppress endogenous insulin secretion by improving
insulin resistance via a mechanism involving a reduction in plasma FFA. This trial is registered with ClinicalTrials.gov NCT01577095.